

**Supplemental Table 4. Odds ratios and 95% confidence intervals comparing disease activity state (PASDAS LDA response<sup>a</sup> and MDA response<sup>b</sup>) at week 24 between guselkumab and placebo within patient subgroups defined by baseline demographics, disease characteristics, and DMARD use at baseline among pooled DISCOVER-1 and DISCOVER-2 patients. Prior to Week 24, patients meeting treatment failure criteria were considered non-responders. Missing data through Weeks 24 and 52 were imputed as non-response.**

	PASDAS LDA Response <sup>a</sup>		MDA Response <sup>b</sup>	
	Odds Ratio (95% CI)			
	GUS 100 mg Q4W	GUS 100 mg Q8W	GUS 100 mg Q4W	GUS 100 mg Q8W
<b>All patients</b>	4.0 (2.6, 6.1)	4.4 (2.9, 6.7)	3.5 (2.2, 5.5)	3.8 (2.4, 5.9)
<b>Sex</b>				
Male	3.7 (2.2, 6.4)	3.9 (2.3, 6.8)	4.8 (2.5, 9.1)	4.9 (2.6, 9.4)
Female	4.1 (2.0, 8.2)	5.1 (2.6, 10.1)	2.3 (1.2, 4.4)	2.8 (1.5, 5.3)
<b>BMI (kg/m<sup>2</sup>)</b>				
<25	4.4 (1.9, 10.3)	4.5 (1.9, 10.4)	4.1 (1.7, 10.1)	4.0 (1.7, 9.9)
25 to <30	3.1 (1.6, 6.1)	3.8 (2.0, 7.2)	3.0 (1.4, 6.2)	4.2 (2.1, 8.4)
≥30	4.9 (2.4, 10.2)	5.4 (2.6, 11.3)	3.7 (1.8, 7.9)	3.3 (1.5, 7.0)
<b>Swollen joint count</b>				
<10	4.9 (2.9, 8.3)	4.2 (2.5, 7.2)	4.3 (2.5, 7.4)	3.6 (2.1, 6.3)
10-15	2.9 (1.2, 6.9)	4.1 (1.8, 9.7)	2.7 (1.0, 7.3)	3.7 (1.4, 9.7)
>15	3.4 (0.9, 13.0)	6.7 (1.9, 24.2)	2.3 (0.6, 9.2)	5.2 (1.4, 19.0)
<b>Tender joint count</b>				
<10	4.7 (2.0, 10.7)	3.6 (1.6, 8.3)	3.8 (1.6, 9.0)	3.2 (1.4, 7.7)
10-15	4.1 (2.0, 8.2)	3.6 (1.8, 7.1)	5.1 (2.4, 10.8)	3.8 (1.8, 8.0)
>15	3.8 (1.8, 8.3)	6.4 (3.0, 13.6)	2.1 (0.9, 4.9)	4.2 (1.9, 9.0)
<b>PsA duration (years)</b>				
<1	2.5 (0.9, 7.0)	5.7 (2.1, 15.0)	1.7 (0.7, 4.3)	2.6 (1.1, 6.2)
≥1 to <3	7.6 (3.0, 19.6)	5.2 (2.0, 13.5)	4.2 (1.6, 11.2)	4.1 (1.5, 10.7)
≥3	3.5 (2.1, 6.0)	3.8 (2.2, 6.5)	4.3 (2.3, 8.0)	4.3 (2.3, 8.0)
<b>BSA affected by psoriasis (%)</b>				
<3	2.8 (1.1, 7.3)	3.2 (1.3, 8.1)	1.9 (0.8, 4.8)	1.5 (0.6, 3.8)
≥3 to <10	2.9 (1.5, 5.7)	3.6 (1.9, 6.9)	2.7 (1.3, 5.6)	2.9 (1.4, 5.8)
≥10 to <20	4.1 (1.6, 10.7)	3.1 (1.1, 8.6)	4.9 (1.6, 15.2)	4.4 (1.4, 14.2)
≥20	8.7 (3.2, 23.4)	11.3 (4.2, 30.5)	9.5 (2.8, 32.8)	15.4 (4.5, 52.5)
<b>CRP (mg/dL)</b>				
<1	3.8 (2.2, 6.6)	4.8 (2.8, 8.3)	3.8 (2.1, 6.8)	4.2 (2.3, 7.6)
1 to <2	13.2 (3.0, 58.6)	12.1 (2.7, 54.7)	4.9 (1.6, 15.3)	3.5 (1.1, 11.4)
≥2	2.4 (1.1, 5.3)	2.7 (1.3, 5.7)	2.0 (0.8, 5.0)	3.3 (1.4, 7.6)
<b>PASI score at baseline (0-72)</b>				
<12	2.8 (1.7, 4.4)	3.2 (2.0, 5.1)	2.6 (1.6, 4.2)	2.8 (1.7, 4.5)
≥12 to <20	6.8 (1.9, 24.9)	7.2 (1.9, 27.2)	13.6 (1.7, 108.5)	12.3 (1.5, 101.6)
≥20	NC (NC, NC)	NC (NC, NC)	17.3 (2.2, 136.5)	24.0 (3.0, 190.9)
<b>csDMARD/MTX use</b>				
None	4.2 (2.1, 8.5)	4.6 (2.3, 9.4)	4.0 (1.8, 8.8)	4.9 (2.2, 10.7)
Any csDMARD	3.9 (2.3, 6.5)	4.3 (2.6, 7.3)	3.3 (1.9, 5.6)	3.3 (1.9, 5.7)
MTX	4.4 (2.5, 7.8)	4.0 (2.3, 7.2)	3.9 (2.2, 6.9)	3.3 (1.8, 6.0)

<sup>a</sup>PASDAS score ≤3.2. The PASDAS score is calculated from a combination of the tender and swollen joint counts, Physical Component Summary Short Form-36 score, physician's global assessment of disease activity, patient's global assessment of disease activity (arthritis and psoriasis), enthesitis, dactylitis count, and CRP.

<sup>b</sup>5/7 MDA criteria are met (tender joint count ≤1, swollen joint count ≤1, psoriasis activity and severity index ≤1, patient's assessment of pain ≤15, patient's global assessment of disease activity ≤20, Health Assessment Questionnaire-Disability Index score ≤0.5, Tender enthesal points ≤1).

BMI=Body mass index, BSA=Body surface area, CI=confidence interval, CRP=C-reactive protein, csDMARD=Conventional synthetic disease-modifying antirheumatic drug, GUS=Guselkumab, LDA=Low disease activity, MDA=Minimal disease activity, MTX=Methotrexate, PASDAS=Psoriatic Arthritis Disease Activity Score, PASI=Psoriasis Area and Severity Index, PsA=Psoriatic arthritis, Q4W/Q8W=every four weeks/every eight weeks